July 31, 2015

Contact:
Corporate Communications,
Astellas Pharma Inc.
TEL +81-3-3244-3201

Financial Results of Astellas for the First Three Months of FY2015 (IFRS)

Japan, July 31, 2015 – Astellas Pharma Inc. (hereinafter referred to as "the Company") today announced the financial results for the first three months of the fiscal year 2015 (FY2015) ending March 31, 2016.

Consolidated financial results for the first three months of FY2015 (April 1, 2015 – June 30, 2015) (core basis)

(Millions of yen)

	First three months of FY2014	**First three months of FY2015**	Change (%)
Sales	295,157	**343,659**	+48,502 (+16.4%)
Core operating profit	65,976	**67,820**	+1,843 (+2.8%)
Core profit for the period	46,409	**45,031**	-1,378 (-3.0%)
Basic core earnings per share (yen)	20.90	**20.57**	-0.33 (-1.6%)

Cautionary statement regarding forward-looking information

This press release includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Consequently, any statements herein do not constitute assurances regarding actual results by the Company. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the Company to market existing and new products effectively, interruptions in production, infringements of the Company's intellectual property rights and the adverse outcome of material litigation.

1. Qualitative information on consolidated financial results for the first three months of FY2015

(1) Information on business performance

<Consolidated financial results (core basis [(Note)])>

Consolidated financial results (core basis) in the first three months of FY2015 showed increases in sales and core operating profit and a decrease in core profit for the period, as follows.

Consolidated financial results (core basis)

(Millions of yen)

	First three months of FY2014	**First three months of FY2015**	Change (%)
Sales	295,157	**343,659**	+48,502 (+16.4%)
Core operating profit	65,976	**67,820**	+1,843 (+2.8%)
Core profit for the period	46,409	**45,031**	-1,378 (-3.0%)
Basic core earnings per share (yen)	20.90	**20.57**	-0.33 (-1.6%)

Research and development (R&D) expenses

(Millions of yen)

	First three months of FY2014	**First three months of FY2015**	Change
R&D expenses	47,643	**55,980**	+8,337

(Note) The Company discloses financial results on a core basis as an indicator of its recurring profitability. Certain items reported in financial results on a full basis that are deemed to be non-recurring items by the Company are excluded as non-core items from these financial results on a core basis. These adjusted items include impairment losses, gain/loss on sales of property, plant and equipment, restructuring costs, loss on disaster, a large amount of losses on compensation or settlement of litigations and other legal disputes, and other items that are deemed to be excluded based on the Company's judgment. A reconciliation table between results on a full basis and results on a core basis is provided on page 21 of the "Supplement Documents for Results 1Q/FY2015."

Impact of exchange rate on financial results

The exchange rates for the yen in the first three months of FY2015 are shown in the table below. The resulting impacts were a ¥17.3 billion increase in sales and a ¥1.8 billion increase in core operating profit.

Average rate	First three months of FY2014	**First three months of FY2015**	Change
US$/¥	102	**121**	¥19 (Weakening of yen)
€/¥	140	**134**	¥6 (Strengthening of yen)

Change from beginning to end of period	As of June 30, 2014	**As of June 30, 2015**
US$/¥	¥2 (Strengthening of yen)	**¥2 (Weakening of yen)**
€/¥	¥3 (Strengthening of yen)	**¥7 (Weakening of yen)**

Sales

Consolidated sales in the first three months of FY2015 increased by 16.4% compared to those in the corresponding period of the previous fiscal year ("year-on-year") to ¥343.7 billion.

- In addition to a new product, XTANDI for the treatment of prostate cancer, sales of overactive bladder (OAB) treatments Vesicare and Betanis / Myrbetriq / BETMIGA grew. Additionally, sales of products including Prograf, an immunosuppressant, increased.

Sales by region

*Sales by region calculated according to locations of sellers.

<Japan>

Sales in Japan increased by 11.3% year-on-year to ¥125.6 billion. Sales in the Japanese market increased by 12.1% year-on-year to ¥122.2 billion.

- There was growth in sales of products including Vesicare, Betanis, the anti-inflammatory and anti-pain drug Celecox, Symbicort for the treatment of bronchial asthma, Micardis for the treatment of hypertension and Bonoteo for the treatment of osteoporosis.
- In addition, new products such as XTANDI contributed to increased sales.
- On the other hand, sales of products including Lipitor for the treatment of hypercholesterolemia and Gaster for the treatment of peptic ulcer and gastritis declined, mainly due to the impact of generics.

<The Americas>

Sales in the Americas increased by 36.9% year-on-year to ¥114.8 billion. The sales on a U.S. dollar basis increased by 15.2% year-on-year to US$946 million.

- In addition to the sales of XTANDI, overall sales of OAB treatments VESIcare and Myrbetriq grew.
- On the other hand, there were decreases in sales of Prograf and income from anticancer drug Tarceva.

<EMEA*>

Sales in EMEA decreased by 0.8% year-on-year to ¥81.7 billion. The sales on a euro basis increased by 3.5% year-on-year to €609 million.

- In addition to XTANDI and overall OAB treatments Vesicare and BETMIGA, sales of Prograf and others grew.

*EMEA: Europe, the Middle East and Africa

<Asia and Oceania>

Sales in Asia and Oceania increased by 34.0% year-on-year to ¥21.5 billion.

- Products such as Prograf and Harnal showed growth in sales, resulting in an increase in revenue.
- In addition, XTANDI contributed to increased sales.

Core operating profit / Core profit for the period

- The increase in sales resulted in a gross profit of ¥253.6 billion, up 15.7% year-on-year. The cost-to-sales ratio rose 0.5 percentage points year-on-year to 26.2%, owing to the foreign exchange rate impact from the elimination of unrealized gains in intra-group transactions and other factors.
- Selling, general and administrative expenses increased by 22.4% year-on-year to ¥118.7 billion, which in addition to increased expenditures for co-promotion of XTANDI in the US, was partly due to the foreign exchange rate impact.
- Research and development (R&D) expenses were ¥56.0 billion, up 17.5% year-on-year, which in addition to increased expenses related to progress of development projects, was partly due to the foreign exchange rate impact. The R&D cost-to-sales ratio was up 0.1 percentage points year-on-year to 16.3%.
- Amortisation of intangible assets was ¥10.9 billion, up 22.8% year-on-year.

As a result of the above, core operating profit increased by 2.8% year-on-year to ¥67.8 billion.

Core profit for the period decreased by 3.0% to ¥45.0 billion due to the year-on-year rise in the income tax burden rate owing to the impact of deferred tax, which was caused by temporary fluctuations of unrealized gains in inventory in the US/EMEA subsidiaries. Basic core earnings per share decreased by 1.6% to ¥20.57.

<Consolidated financial results (full basis)>

Consolidated financial results on a full basis in the first three months of FY2015 are shown in the table below. Sales, operating profit, profit before tax and profit for the period increased.

Items at a total of ¥7.2 billion including impairment losses for property, plant and equipment, which are excluded from results on a core basis, were recorded in "other expense." In addition, gain on sales of available-for-sale financial assets at a total of ¥5.5 billion was recorded in "finance income." "Other expense" and gain on sales of available-for-sale financial assets in the same period of the previous fiscal year were ¥18.1 billion and ¥0.9 billion, respectively.

Consolidated financial results (full basis)

(Millions of yen)

	First three months of FY2014	**First three months of FY2015**	Change (%)
Sales	295,157	**343,659**	+48,502 (+16.4%)
Operating profit	50,565	**61,911**	+11,346 (+22.4%)
Profit before tax	50,278	**67,664**	+17,386 (+34.6%)
Profit for the period	35,861	**44,622**	+8,760 (+24.4%)
Basic earnings per share (yen)	16.15	**20.38**	+4.23 (+26.2%)
Comprehensive income	22,519	**71,834**	+49,315 (+219.0%)

(2) Information on financial position

1) Assets, equity and liabilities

An overview of the consolidated statement of financial position as of June 30, 2015 and the main changes from the end of the previous fiscal year are shown below.

Assets

Total assets as of June 30, 2015 saw a decrease of ¥13.6 billion compared to the end of the previous fiscal year to ¥1,780.0 billion.

<Non-current assets> ¥824.8 billion (a decrease of ¥2.8 billion)

- Other intangible assets decreased by ¥7.6 billion compared to the end of the previous fiscal year to ¥288.2 billion.

<Current assets> ¥955.2 billion (a decrease of ¥10.7 billion)

- Cash and cash equivalents decreased by ¥24.9 billion compared to the end of the previous fiscal year to ¥371.5 billion.

Equity

Total equity as of June 30, 2015 saw an increase of ¥15.9 billion compared to the end of the previous fiscal year to ¥1,333.8 billion, making the ratio of owners' equity to gross assets 74.9%.

- While profit for the period stood at ¥44.6 billion, the Company paid ¥35.1 billion of dividends of surplus and acquired ¥20.9 billion of own shares.
- Cancellation of treasury shares totaling ¥49.6 billion (38 million shares) was carried out on May 29, 2015.
- In addition, the effect of foreign currency translation adjustments increased equity by ¥28.8 billion.

Liabilities

Total liabilities decreased by ¥29.5 billion compared to the end of the previous fiscal year to ¥446.2 billion.

<Non-current liabilities> ¥55.0 billion (an increase of ¥0.2 billion)
<Current liabilities> ¥391.2 billion (a decrease of ¥29.7 billion)

2) Cash flow

Cash flows from operating activities

Net cash flows from operating activities decreased year-on-year by ¥31.0 billion to ¥29.6 billion.

- Income tax paid was ¥25.9 billion.

Cash flows from investing activities

Net cash flows used in investing activities was ¥8.2 billion, a decrease in outflow of ¥3.9 billion year-on-year.

- Purchases of property, plant and equipment used cash of ¥9.2 billion and purchase of intangible assets used cash of ¥5.9 billion, while proceeds from sales of available-for-sale financial assets provided cash of ¥7.9 billion.

Cash flows from financing activities

Net cash flows used in financing activities was ¥56.2 billion, a decrease in outflow of ¥5.2 billion year-on-year.

- Dividends paid totaled ¥35.1 billion. Other outflow included cash of ¥20.9 billion used for the acquisition of own shares.

As a result of the above, cash and cash equivalents totaled ¥371.5 billion as of June 30, 2015, a decrease of ¥24.9 billion compared to the end of the previous fiscal year.

(3) Information on consolidated business forecasts for FY2015 and other forward-looking statements

The Company's business forecasts for FY2015 are presented on a core basis and full basis.
The consolidated full-year business forecasts for the fiscal year ending March 31, 2016 (FY2015) are shown below. The Company has chosen to leave its business forecasts unchanged from the consolidated full-year business forecasts announced in May 2015 because it does not expect large deviations from the forecasts.

Consolidated full-year business forecasts (core basis)

(Millions of yen – fractions rounded)

	FY2014 Full-year results	**FY2015 Full-year forecasts**	Change (%)
Sales	1,247,259	**1,362,000**	+114,741 (+9.2%)
Core operating profit	216,500	**238,000**	+21,500 (+9.9%)
Core profit for the year	153,244	**170,000**	+16,756 (+10.9%)
Basic core earnings per share (yen)	69.37	**78.08**	+8.71 (+12.6%)

Consolidated full-year business forecasts (full basis)

(Millions of yen – fractions rounded)

	FY2014 Full-year results	**FY2015 Full-year forecasts**	Change (%)
Sales	1,247,259	**1,362,000**	+114,741 (+9.2%)
Operating profit	185,663	**238,000**	+52,337 (+28.2%)
Profit before tax	189,683	**239,000**	+49,317 (+26.0%)
Profit for the year	135,856	**170,000**	+34,144 (+25.1%)
Basic earnings per share (yen)	61.50	**78.08**	+16.58 (+27.0%)

(Note) The forecasts for basic core earnings per share and basic earnings per share reflect acquisitions of own shares carried out from May 28 to July 10, 2015.

2. Matters Related to Summary Information (Notes)

(1) Changes in Accounting Policies and Accounting Estimates

The significant accounting policies adopted for the condensed interim consolidated financial statements of Astellas Pharma Inc. and its subsidiaries (collectively, the"Group") for the three months ended 30 June 2015 are the same as those applied for its consolidated financial statements for the fiscal year ended 31 March 2015, except for the new standard listed below.

The Group calculated income tax expense for the three months ended 30 June 2015 based on the estimated average annual effective tax rate.

The following accounting standard is newly applied by the Group from the three months ended 30 June 2015. The standard does not have a material impact on the Group's condensed interim consolidated financial statements.

IFRS		Summary of new standard
IAS 19	Employee Benefits	Clarification of accounting for contributions by employees or third parties

3. Condensed Interim Consolidated Financial Statements
(1) Condensed Interim Consolidated Statements of Income

（Millions of Yen）

	Three months ended 30 June 2014	Three months ended 30 June 2015
Sales	295,157	343,659
Cost of sales	(75,983)	(90,079)
Gross profit	219,174	253,581
Selling, general and administrative expenses	(96,908)	(118,662)
Research and development expenses	(47,643)	(55,980)
Amortisation of intangible assets	(8,864)	(10,882)
Share of profits (losses) of associates and joint ventures	218	(236)
Other income	2,700	1,262
Other expense	(18,111)	(7,171)
Operating profit	50,565	61,911
Finance income	1,825	6,029
Finance expense	(2,112)	(277)
Profit before tax	50,278	67,664
Income tax expense	(14,417)	(23,042)
Profit for the period	35,861	44,622
Profit attributable to:		
Owners of the parent	35,861	44,622
Earnings per share		
Basic（Yen）	16.15	20.38
Diluted（Yen）	16.13	20.35

(2) Condensed Interim Consolidated Statements of Comprehensive Income

(Millions of Yen)

	Three months ended 30 June 2014	Three months ended 30 June 2015
Profit for the period	35,861	44,622
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Remeasurements of defined benefit plans	537	1,254
Subtotal	537	1,254
Items that may be reclassified subsequently to profit or loss		
Foreign currency translation adjustments	(12,792)	28,762
Fair value movements on available-for-sale financial assets	(1,087)	(2,803)
Subtotal	(13,879)	25,959
Other comprehensive income, net of tax	(13,342)	27,213
Total comprehensive income	22,519	71,834
Total comprehensive income attributable to:		
Owners of the parent	22,519	71,834

(3) Condensed Interim Consolidated Statements of Financial Position

(Millions of Yen)

	As of 31 March 2015	As of 30 June 2015
Assets		
Non-current assets		
Property, plant and equipment	202,869	205,520
Goodwill	136,337	138,924
Other intangible assets	295,844	288,245
Trade and other receivables	15,588	18,732
Investments in associates and joint ventures	2,007	2,228
Deferred tax assets	51,199	51,972
Other financial assets	110,091	103,860
Other non-current assets	13,685	15,291
Total non-current assets	827,621	824,772
Current assets		
Inventories	156,907	157,687
Trade and other receivables	332,923	360,568
Income tax receivable	6,918	3,672
Other financial assets	59,908	44,135
Other current assets	12,732	17,261
Cash and cash equivalents	396,430	371,537
Sub total	965,819	954,861
Assets held for sale	139	370
Total current assets	965,958	955,231
Total assets	1,793,578	1,780,003

(Millions of Yen)

	As of 31 March 2015	As of 30 June 2015
Equity and liabilities		
Equity		
Share capital	103,001	103,001
Capital surplus	176,822	176,822
Treasury shares	(86,997)	(58,281)
Retained earnings	905,083	866,255
Other components of equity	220,007	246,000
Total equity attributable to owners of the parent	1,317,916	1,333,796
Total equity	1,317,916	1,333,796
Liabilities		
Non-current liabilities		
Trade and other payables	90	925
Deferred tax liabilities	38	—
Retirement benefit liabilities	30,059	30,040
Provisions	4,817	6,446
Other financial liabilities	626	805
Other non-current liabilities	19,142	16,766
Total non-current liabilities	54,771	54,982
Current liabilities		
Trade and other payables	226,602	199,513
Income tax payable	14,124	7,069
Provisions	85,423	88,877
Other financial liabilities	1,339	2,860
Other current liabilities	93,403	92,906
Total current liabilities	420,890	391,225
Total liabilities	475,662	446,207
Total equity and liabilities	1,793,578	1,780,003

(4) Condensed Interim Consolidated Statements of Changes in Equity

(Millions of Yen)

	Equity attributable to owners of the parent					
					Other components of equity	
	Share capital	Capital surplus	Treasury shares	Retained earnings	Subscription rights to shares	Foreign currency translation adjustments
As of 1 April 2014	103,001	176,822	(54,535)	864,830	2,110	147,660
Comprehensive income						
Profit for the period	—	—	—	35,861	—	—
Other comprehensive income	—	—	—	—	—	(12,792)
Total comprehensive income	—	—	—	35,861	—	(12,792)
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(30,007)	—	—	—
Disposals of treasury shares	—	—	29	(5)	(15)	—
Cancellation of treasury shares	—	—	25,398	(25,398)	—	—
Dividends	—	—	—	(31,236)	—	—
Share-based payments	—	—	—	—	89	—
Transfers	—	—	—	537	—	—
Total transactions with owners of the parent	—	—	(4,581)	(56,102)	74	—
As of 30 June 2014	103,001	176,822	(59,115)	844,590	2,184	134,868

As of 1 April 2015	103,001	176,822	(86,997)	905,083	2,241	177,306
Comprehensive income						
Profit for the period	—	—	—	44,622	—	—
Other comprehensive income	—	—	—	—	—	28,762
Total comprehensive income	—	—	—	44,622	—	28,762
Transactions with owners of the parent						
Acquisition of treasury shares	—	—	(20,937)	—	—	—
Disposals of treasury shares	—	—	76	(37)	(39)	—
Cancellation of treasury shares	—	—	49,577	(49,577)	—	—
Dividends	—	—	—	(35,090)	—	—
Share-based payments	—	—	—	—	73	—
Transfers	—	—	—	1,254	—	—
Total transactions with owners of the parent	—	—	28,716	(83,450)	34	—
As of 30 June 2015	103,001	176,822	(58,281)	866,255	2,274	206,068

(Millions of Yen)

	Equity attributable to owners of the parent				Total equity
	Other components of equity			Total	
	Fair value movements on available-for-sale financial assets	Remeasurements of defined benefit plans	Total		
As of 1 April 2014	28,588	—	178,359	1,268,476	1,268,476
Comprehensive income					
Profit for the period	—	—	—	35,861	35,861
Other comprehensive income	(1,087)	537	(13,342)	(13,342)	(13,342)
Total comprehensive income	(1,087)	537	(13,342)	22,519	22,519
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(30,007)	(30,007)
Disposals of treasury shares	—	—	(15)	8	8
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(31,236)	(31,236)
Share-based payments	—	—	89	89	89
Transfers	—	(537)	(537)	—	—
Total transactions with owners of the parent	—	(537)	(464)	(61,146)	(61,146)
As of 30 June 2014	27,502	—	164,553	1,229,850	1,229,850

As of 1 April 2015	40,461	—	220,007	1,317,916	1,317,916
Comprehensive income					
Profit for the period	—	—	—	44,622	44,622
Other comprehensive income	(2,803)	1,254	27,213	27,213	27,213
Total comprehensive income	(2,803)	1,254	27,213	71,834	71,834
Transactions with owners of the parent					
Acquisition of treasury shares	—	—	—	(20,937)	(20,937)
Disposals of treasury shares	—	—	(39)	0	0
Cancellation of treasury shares	—	—	—	—	—
Dividends	—	—	—	(35,090)	(35,090)
Share-based payments	—	—	73	73	73
Transfers	—	(1,254)	(1,254)	—	—
Total transactions with owners of the parent	—	(1,254)	(1,220)	(55,954)	(55,954)
As of 30 June 2015	37,658	—	246,000	1,333,796	1,333,796

(5) Condensed Interim Consolidated Statements of Cash Flows

(Millions of Yen)

	Three months ended 30 June 2014	Three months ended 30 June 2015
Cash flows from operating activities		
Profit before tax	50,278	67,664
Depreciation and amortisation	15,453	17,374
Impairment losses and reversal of impairment losses	8,076	6,357
Finance income and expense	287	(5,752)
(Increase) decrease in inventories	(11,715)	4,174
(Increase) decrease in trade and other receivables	4,551	(23,149)
Increase (decrease) in trade and other payables	4,575	(31,544)
Other	11,542	20,378
Cash generated from operations	83,048	55,501
Income tax paid	(22,396)	(25,859)
Net cash flows from operating activities	60,653	29,642
Cash flows from investing activities		
Purchases of property, plant and equipment	(5,348)	(9,236)
Proceeds from sales of property, plant and equipment	3,327	342
Purchase of intangible assets	(11,519)	(5,924)
Purchase of available-for-sale financial assets	(34)	(8)
Proceeds from sales of available-for-sale financial assets	1,547	7,922
Interest and dividends received	1,211	576
Other	(1,331)	(1,922)
Net cash flows used in investing activities	(12,145)	(8,250)
Cash flows from financing activities		
Acquisition of treasury shares	(30,007)	(20,937)
Dividends paid to owners of the parent	(31,236)	(35,090)
Other	(189)	(196)
Net cash flows used in financing activities	(61,432)	(56,223)
Effect of exchange rate changes on cash and cash equivalents	(5,435)	9,937
Net increase (decrease) in cash and cash equivalents	(18,359)	(24,893)
Cash and cash equivalents at the beginning of the year	391,374	396,430
Cash and cash equivalents at the end of the period	373,015	371,537

(6) Notes on going concern assumption

Not applicable.

Supplement Documents for Results 1Q/FY2015 [IFRS]

Astellas Pharma Inc.

- Financial Results of 1Q/FY2015
- Pipeline list

Cautionary statement regarding forward-looking information

This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.

1. Consolidated Results (Full Basis)

billion yen

	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	295.2	343.7	48.5	16.4%	1,362.0	9.2%
Cost of sales	76.0	90.1	14.1	18.6%		
Ratio to Sales	25.7%	26.2%				
Gross profit	219.2	253.6	34.4	15.7%		
SG&A expenses	96.9	118.7	21.8	22.4%		
Ratio to Sales	32.8%	34.5%				
Advertising and Sales Promotion	28.2	41.6	13.5	47.7%		
Personnel expenses	42.4	45.1	2.7	6.3%		
Other	26.3	32.0	5.6	21.4%		
R&D expenses	47.6	56.0	8.3	17.5%	229.0	10.8%
Ratio to Sales	16.1%	16.3%			16.8%	
Amortisation of intangible assets	8.9	10.9	2.0	22.8%		
Share of profits of associates and joint ventures	0.2	-0.2	-0.5	-208.6%		
Other income	2.7	1.3	-1.4	-53.2%		
Gain on sales of property, plant and equipment	0.0	0.1	0.1	799.6%		
Net foreign exchange gains	2.5	0.6	-1.8	-74.3%		
Other expense	18.1	7.2	-10.9	-60.4%		
Loss on sales and disposal of property, plant and equipment	0.2	0.1	-0.1	-54.9%		
Impairment losses	8.1	6.6	-1.5	-18.7%		
Restructuring costs	9.3	-	-9.3	-		
Operating profit	50.6	61.9	11.3	22.4%	238.0	28.2%
Ratio to Sales	17.1%	18.0%			17.5%	
Finance income	1.8	6.0	4.2	230.4%		
Gain on sales of available-for-sale financial assets	0.9	5.5	4.6	540.2%		
Finance expense	2.1	0.3	-1.8	-86.9%		
Impairment losses for available-for-sale financial assets	2.0	0.0	-2.0	-98.5%		
Profit before tax	50.3	67.7	17.4	34.6%	239.0	26.0%
Ratio to Sales	17.0%	19.7%			17.5%	
Income tax expense	14.4	23.0	8.6	59.8%		
Profit for the period	35.9	44.6	8.8	24.4%	170.0	25.1%
Ratio to Sales	12.1%	13.0%			12.5%	
Comprehensive income for the period	22.5	71.8	49.3	219.0%		

2. Consolidated Results (Core Basis)

billion yen

	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales	295.2	343.7	48.5	16.4%	1,362.0	9.2%
Cost of sales	76.0	90.1	14.1	18.6%		
Ratio to Sales	25.7%	26.2%				
Gross profit	219.2	253.6	34.4	15.7%		
SG&A expenses	96.9	118.7	21.8	22.4%		
Ratio to Sales	32.8%	34.5%				
Advertising and Sales Promotion	28.2	41.6	13.5	47.7%		
Personnel expenses	42.4	45.1	2.7	6.3%		
Other	26.3	32.0	5.6	21.4%		
R&D expenses	47.6	56.0	8.3	17.5%	229.0	10.8%
Ratio to Sales	16.1%	16.3%			16.8%	
Amortisation of intangible assets	8.9	10.9	2.0	22.8%		
Share of profits of associates and joint ventures	0.2	-0.2	-0.5	-208.6%		
Operating profit	66.0	67.8	1.8	2.8%	238.0	9.9%
Ratio to Sales	22.4%	19.7%			17.5%	
Finance income	1.0	0.6	-0.4	-43.2%		
Finance expense	0.1	0.1	-0.0	-20.5%		
Profit before Tax	66.8	68.3	1.4	2.2%		
Ratio to Sales	22.6%	19.9%				
Income tax expense	20.4	23.3	2.8	13.8%		
Profit for the period	46.4	45.0	-1.4	-3.0%	170.0	10.9%
Ratio to Sales	15.7%	13.1%			12.5%	

3. Exchange Rate

yen

	FY14 APR. - JUN.Ave.	FY15 APR. - JUN.Ave.	FY14 End	FY15 1Q End	Forecasts FY15 Full Year
USD/Yen	102	121	120	122	120
EUR/Yen	140	134	130	137	125

∗ Exchange rate fluctuations had positive impact by 17.3 billion yen on sales and positive impact by 1.8 billion yen on Core operating profit in Q1/FY2015

4. Reconciliation of Full Basis to Core Basis

Billion yen

Account item	FY14 APR. - JUN.			FY15 APR. - JUN.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**295.2**	**-**	**295.2**	**343.7**	**-**	**343.7**
Cost of sales	76.0	-	76.0	90.1	-	90.1
Gross profit	**219.2**	**-**	**219.2**	**253.6**	**-**	**253.6**
SG&A expenses	96.9	-	96.9	118.7	-	118.7
R&D expenses	47.6	-	47.6	56.0	-	56.0
Amortisation of intangible assets	8.9	-	8.9	10.9	-	10.9
Share of profits of associates and joint ventures	0.2	-	0.2	-0.2	-	-0.2
Other income *1	2.7	-2.7	-	1.3	-1.3	-
Other expense *1	18.1	-18.1	-	7.2	-7.2	-
Operating profit	**50.6**	**15.4**	**66.0**	**61.9**	**5.9**	**67.8**
Finance income *2	1.8	-0.9	1.0	6.0	-5.5	0.6
Finance expense *2	2.1	-2.0	0.1	0.3	-0.2	0.1
Profit before tax	**50.3**	**16.6**	**66.8**	**67.7**	**0.6**	**68.3**
Income tax expense	14.4	6.0	20.4	23.0	0.2	23.3
Profit for the period	**35.9**	**10.5**	**46.4**	**44.6**	**0.4**	**45.0**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, loss on the restructuring, and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Segment Information by Region

billion yen

		FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Sales		295.2	343.7	48.5	16.4%	1,362.0	9.2%
	Japan	112.8	125.6	12.8	11.3%	521.7	4.6%
	Ratio to Sales	38.2%	36.6%			38.3%	
	Americas	83.8	114.8	30.9	36.9%	439.8	21.8%
	Ratio to Sales	28.4%	33.4%			32.3%	
	EMEA	82.4	81.7	-0.7	-0.8%	309.4	-1.3%
	Ratio to Sales	27.9%	23.8%			22.7%	
	Asia and Oceania	16.1	21.5	5.5	34.0%	91.1	22.8%
	Ratio to Sales	5.4%	6.3%			6.7%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

6. Depreciation/Amortisation

billion yen

		FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Depreciation(PP&E)							
	Consolidated	5.3	5.0	-0.2	-4.5%	22.5	5.5%
Amortisation(Intangible Assets) *							
	Consolidated	10.2	12.4	2.2	21.1%	53.0	20.0%

* Amortisation(Intangible Assets): Including amortisation of software, etc.

7. Sales of major products

1)Sales of global products

billion yen

	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
XTANDI	23.4	59.1	35.7	152.8%	229.4	67.2%
US	14.7	36.2	21.5	146.7%	141.6	65.3%
ex-US	8.7	22.8	14.2	163.2%	87.8	70.5%
Japan	1.5	6.8	5.3	346.5%	23.0	54.7%
Americas (ex-US)	0.4	1.0	0.6	151.6%	4.2	58.1%
EMEA	6.7	14.6	7.9	117.3%	58.8	75.8%
Asia and Oceania	0.0	0.4	0.4	-	1.9	212.8%
Eligard	5.1	4.4	-0.6	-12.3%	18.1	-4.6%
EMEA	5.1	4.4	-0.7	-12.9%	17.9	-5.5%
Asia and Oceania	0.0	0.0	0.0	349.7%	0.2	256.0%
Vesicare	33.0	35.4	2.4	7.1%	132.9	-1.7%
Japan	5.3	6.8	1.6	29.6%	26.4	3.2%
Americas	15.5	17.1	1.5	9.9%	63.8	3.9%
EMEA	11.0	10.2	-0.8	-7.2%	36.0	-14.9%
Asia and Oceania	1.2	1.2	0.1	7.6%	6.3	18.1%
Betanis/Myrbetriq/Betmiga	10.7	18.1	7.4	69.1%	79.3	49.1%
Japan	2.7	4.9	2.2	81.0%	23.0	55.5%
Americas	6.2	9.8	3.7	59.7%	40.8	46.4%
EMEA	1.8	3.3	1.5	79.7%	14.8	44.0%
Asia and Oceania	0.0	0.1	0.1	447.7%	0.6	255.8%
Harnal	13.7	14.2	0.5	3.4%	53.7	-4.1%
Sales by Astellas	12.5	13.3	0.8	6.2%	49.5	-4.6%
Japan	3.9	3.4	-0.5	-11.6%	12.9	-14.2%
EMEA	4.5	4.7	0.2	3.7%	14.7	-18.0%
Asia and Oceania	4.0	5.0	1.0	25.5%	21.2	16.2%
Bulk and Royalties	1.2	0.9	-0.3	-25.4%	4.2	1.4%
Prograf	47.0	50.4	3.3	7.1%	192.6	-1.1%
Sales by Astellas	46.2	49.9	3.7	8.0%	190.1	-0.4%
Japan (Including Graceptor)	11.4	12.7	1.3	11.0%	49.9	3.7%
Americas	8.8	8.4	-0.4	-4.5%	32.4	-2.1%
EMEA	18.6	19.6	1.0	5.2%	68.6	-11.7%
Advagraf	6.6	7.5	0.9	13.8%		
Asia and Oceania	7.3	9.2	1.9	25.7%	39.2	22.5%
Exports to third parties	0.9	0.5	-0.4	-41.3%	2.5	-33.9%
Funguard/Mycamine	8.9	10.3	1.4	16.3%	40.6	4.6%
Japan	2.5	2.9	0.4	16.5%	12.2	3.5%
Americas	2.8	3.3	0.4	15.5%	12.3	-0.9%
EMEA	2.7	2.8	0.2	6.5%	9.9	-3.0%
Asia and Oceania	0.9	1.3	0.4	49.2%	6.2	40.6%
Protopic	6.0	4.7	-1.4	-22.5%	13.7	-36.9%
Americas	3.1	1.5	-1.6	-51.7%	2.6	-75.1%
EMEA	2.1	1.8	-0.3	-13.4%	6.6	-15.4%
Asia and Oceania	0.8	1.3	0.5	66.7%	4.3	25.4%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2)Sales of products in Japan

billion yen

<Global products>	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
XTANDI	1.5	6.8	5.3	346.5%	23.0	54.7%
Vesicare	5.3	6.8	1.6	29.6%	26.4	3.2%
Betanis	2.7	4.9	2.2	81.0%	23.0	55.5%
Harnal	3.9	3.4	-0.5	-11.6%	12.9	-14.2%
Prograf （Including Graceptor）	11.4	12.7	1.3	11.0%	49.9	3.7%
Funguard	2.5	2.9	0.4	16.5%	12.2	3.5%
<Local products in Japan>						
Micardis [Family]	23.3	24.8	1.5	6.3%	105.2	9.9%
Micombi	2.7	2.7	-0.1	-3.0%		
Micamlo	5.7	6.5	0.8	14.5%		
Celecox	8.4	11.8	3.5	41.4%	49.6	18.9%
Symbicort	6.2	9.0	2.8	44.2%	38.1	15.6%
Bonoteo	2.6	3.7	1.0	39.8%	14.4	11.1%
Geninax	2.3	2.8	0.5	20.9%	10.4	0.4%
Vaccines	5.3	6.6	1.3	24.6%	42.4	9.2%
Argamate	1.5	1.5	0.1	6.5%	6.4	8.1%
Kiklin	0.3	0.4	0.1	23.2%	2.2	46.1%
Gonax	0.8	0.9	0.2	26.1%	4.2	24.9%
Cimzia	1.1	1.6	0.5	40.1%	7.5	49.1%
Suglat	2.5	2.0	-0.5	-18.2%	11.0	167.9%
Lipitor*	9.6	8.3	-1.3	-13.1%	30.6	-16.5%
Myslee	4.8	4.7	-0.2	-3.6%	18.1	-6.4%
Gaster	4.8	3.9	-0.8	-17.4%	15.1	-16.3%
Seroquel	3.4	3.0	-0.5	-13.4%	10.6	-15.5%
Total Rx Sales In Japanese market	109.0	122.2	13.2	12.1%	507.0	5.2%

- Sales of products in Japan are shown in a gross sales basis.

*Transfer of Distribution for Caduet to Pfizer on April 1, 2015. Sales in FY2014 exclude sales of Caduet.

3)Sales of products in Americas and EMEA

billion yen

	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Scan* (Americas)	16.6	20.8	4.2	25.1%	74.3	12.0%
Lexiscan	16.5	20.8	4.3	26.2%		
AmBisome (Americas)	1.9	2.8	0.9	47.7%	9.7	7.9%
Tarceva	13.6	13.1	-0.4	-3.2%		
(US)	9.6	9.7	0.1	0.5%		
(ex-US)	3.9	3.4	-0.5	-12.3%		
Qutenza (EMEA)	0.4	0.5	0.1	16.3%		
DIFICLIR (EMEA)	0.5	0.6	0.2	34.7%		

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4)Sales in Americas and EMEA(Local currency)

Unit:M$

Americas	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Net Sales	821	946	125	15.2%	3,665	11.6%
XTANDI	148	307	159	107.8%	1,215	51.2%
US	144	298	155	107.6%	1,180	51.4%
Americas (ex-US)	4	9	5	111.8%	35	44.9%
Tarceva	133	108	-25	-18.5%		
US	94	80	-14	-15.4%		
ex-US	38	28	-10	-26.1%		
VESIcare	152	141	-11	-7.5%	532	-4.8%
Myrbetriq	60	81	21	34.4%	340	34.1%
Prograf	86	69	-17	-19.6%	270	-10.3%
Scan*	163	171	9	5.3%	619	2.6%
Lexiscan	161	171	10	6.2%		
MYCAMINE	28	27	-1	-2.8%	102	-9.2%
AmBisome	19	23	5	24.3%	81	-1.1%
Protopic	31	12	-18	-59.4%	21	-77.2%

* Adenoscan + Lexiscan

Unit:M€

EMEA	FY14 APR. - JUN.	FY15 APR. - JUN.	Change	Change (%)	Forecasts FY15 Full Year	Change from FY14 Change (%)
Net Sales	589	609	21	3.5%	2,475	9.6%
XTANDI	48	109	61	126.9%	470	95.2%
Eligard	36	33	-3	-9.1%	143	4.9%
Vesicare	78	76	-2	-3.1%	288	-5.5%
BETMIGA	13	25	12	87.7%	119	59.9%
Harnal (Omnic)	41	42	1	1.8%	151	-5.0%
Sales by Astellas	32	35	3	8.2%	118	-9.0%
Capsule	16	18	2	14.3%	60	-4.7%
OCAS	16	17	0	2.4%	58	-13.1%
Bulk and Royalties	9	7	-2	-22.1%	33	12.5%
Prograf	139	150	11	7.6%	569	-3.1%
Sales by Astellas	133	146	13	9.8%	549	-2.0%
Advagraf	47	56	9	18.8%		
Exports to third parties	6	4	-2	-38.8%	20	-26.6%
MYCAMINE	19	21	2	11.2%	80	7.7%
Protopic	15	14	-1	-9.5%	53	-6.1%
Qutenza	3	4	1	21.5%		
DIFICLIR	3	5	1	40.7%		

- EMEA: Europe, Middle East and Africa

8.Consolidated statements of financial position

Billion yen

			31-Mar-15	30-Jun-15	
			Amount	Amount	Change
Assets			**1,793.6**	**1,780.0**	**-13.6**
	Non-current assets		**827.6**	**824.8**	**-2.8**
		Property, plant and equipment	202.9	205.5	2.7
		Goodwill	136.3	138.9	2.6
		Other intangible assets	295.8	288.2	-7.6
		Trade and other receivables	15.6	18.7	3.1
		Investments in associates and joint ventures	2.0	2.2	0.2
		Deferred tax assets	51.2	52.0	0.8
		Other financial assets	110.1	103.9	-6.2
		Other non-current assets	13.7	15.3	1.6
	Current assets		**966.0**	**955.2**	**-10.7**
		Inventories	156.9	157.7	0.8
		Trade and other receivables	332.9	360.6	27.6
		Income tax receivable	6.9	3.7	-3.2
		Other financial assets	59.9	44.1	-15.8
		Other current assets	12.7	17.3	4.5
		Cash and cash equivalents	396.4	371.5	-24.9
		Assets held for sale	0.1	0.4	0.2

Billion yen

	31-Mar-15	30-Jun-15	
	Amount	Amount	Change
Equity and Liabilities	**1,793.6**	**1,780.0**	**-13.6**
Equity	**1,317.9**	**1,333.8**	**15.9**
Equity attributable to owners of the parent	**1,317.9**	**1,333.8**	**15.9**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.8	-
Treasury shares	-87.0	-58.3	28.7
Retained earnings	905.1	866.3	-38.8
Other components of equity	220.0	246.0	26.0
Liabilities	**475.7**	**446.2**	**-29.5**
Non-current liabilities	**54.8**	**55.0**	**0.2**
Trade and other payables	0.1	0.9	0.8
Deferred tax liabilities	0.0	-	-0.0
Retirement benefit liabilities	30.1	30.0	-0.0
Provisions	4.8	6.4	1.6
Other financial liabilities	0.6	0.8	0.2
Other non-current liabilities	19.1	16.8	-2.4
Current liabilities	**420.9**	**391.2**	**-29.7**
Trade and other payables	226.6	199.5	-27.1
Income tax payable	14.1	7.1	-7.1
Provisions	85.4	88.9	3.5
Other financial liabilities	1.3	2.9	1.5
Other current liabilities	93.4	92.9	-0.5

R&D Pipeline (As of July 2015)

Changed underlined items from the previous announcement on May 11th, 2015

1. Global Development

(1) Phase-III / Phase-II (1/3)

*Compounds with "In-house" in this column include one discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor*	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Non-Metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III	Oral	Medivation	New indication
		Breast cancer	US/Europe Phase-II			New indication
		Hepatocellular carcinoma	US/Europe Phase-II			New indication
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			

(1) Phase-III / Phase-II (2/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	US/Europe/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Merck	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan Phase-III US/Europe Phase-II	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-II	Oral	FibroGen	
ASP2215	FLT3/AXL inhibitor	Acute myeloid leukemia	US/Europe/Japan/Asia Phase-III	Oral	In-house	
		Non-small cell lung cancer	US/Japan/Asia Phase-I			

(1) Phase-III / Phase-II (3/3)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
		Prostate cancer	Europe Phase-I			
ASP8477	Inhibition of central sensitization	Neuropathic pain	Europe Phase-II	Oral	In-house	
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	Japan/Asia Phase-II US Phase I	Oral	In-house	
ASP3662	11beta-HSD1 inhibitor	Painful diabetic peripheral neuropathy	US Phase-II	Oral	In-house	
		Alzheimer's disease	US Phase-I			
CK-2127107	Fast skeletal tropoinin activator	Spinal muscular atrophy	US Phase-II	Oral	Cytokinetics	

2. Local Development: Japan

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
certolizumab pegol	Cimzia (May 2015)	PEGylated anti-tumor necrosis factor-alpha antibody	Treatment of rheumatoid arthritis (including inhibition of progression of bone structural damange)*	Japan	Injection	UCB	New indication
YM060 ramosetron	Irribow (May 2015)	5-HT_3 receptor antagonist	Diarrhea-predominant irritable bowel syndrome**	Japan	Oral	In-house	New indication

*Label was expanded so that Cimzia can be given to patients with high risk of progression of structural damage, even they have not received prior treatment with anti-rheumatic drugs.

**Label was expanded so that Irribow can be given to female patients with diarrhea-predominant irritable bowel syndrome.

(2) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients not on dialysis with chronic kidney disease	Japan Filed (Mar. 2015)	Oral	Amgen	New indication
AMG 145 evolocumab	Anti-PCSK-9 monoclonal antibody	Hypercholesterolemia	Japan Filed (Mar. 2015)	Injection	Amgen (co-development with Amgen Astellas)	

(3) Phase-III / Phase-II

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
FK949E quetiapine	Serotonin / dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ASP0456 linaclotide	Guanylate cyclase type-C receptor agonist	Irritable bowel syndrome with constipation	Japan Phase-III	Oral	Ironwood	
		Chronic constipation	Japan Phase-II			
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Bioequivalence study	Oral	Amgen	New formulation
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	Japan Phase-II	Oral	In-house (co-development with Kotobuki)	New indication

3. Local Development: Europe

(1) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
NGX-4010 capsaicin	TRPV1 agonist	Peripheral neuropathic pain in diabetic patients	Europe Filed (Dec. 2014)	Patch	HealthCare Royalty Partners	New indication

4. Local Development: US

(1) Phase-III / Phase-II

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
isavuconazonium sulfate	Azole antifungal	Candidemia / Invasive candidiasis	US Phase-III	Injection Oral	Basilea	New indication

5. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Licensor
AGS-16C3F	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP5878	Cancer	Oral	In-house
ASP7962	Osteoarthritis, Chronic low back pain	Oral	In-house
YM178 mirabegron	Neurogenic detrusor overactivity and idiopathic overactive bladder in pediatric patients	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP5633	Stress urinary incontinence	Oral	In-house
ASP2205	Stress urinary incontinence	Oral	In-house
ASP5094	Rheumatoid arthritis	Injection	In-house
ASP6858	Chronic kidney disease	Oral	In-house
AMG 103 blinatumomab	Acute lymphoblastic leukemia	Injection	Amgen (co-development with Amgen Astellas)
ASP4132	Cancer	Oral	In-house
ASP4345	Cognitive impairment associated with schizophrenia	Oral	In-house
ASP6282	Underactive bladder	Oral	In-house
ASP4070 (JRC2-LAMP-vax)	Pollinosis caused by Japanese red cedar	Injection	Immunomic Therapeutics

6. Project Discontinued

Code No. Generic Name	Target Disease	Area / Phase	Reason
YM533 beraprost sodium	Chronic renal failure (primary glomerular disease or nephrosclerosis)	Japan/Asia Phase-III	Discontinued the development because sufficient results for filing were not obtained in the Phase 2b/3 study.

7. Other items changed from the previous financial announcement on May 11th, 2015

-Removed the description of Tarceva (erlotinib), for which extension of exclusivity period was granted in the US.

-Removed the description of CRESEMBA (isavuconazonium sulfate) in invasive aspergillosis and invasive mucormycosis, which was launched in April 2015 in the US.